{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.03","upperLimit":"0.95","value":"0.03"},{"groupId":"OG001","lowerLimit":"0.03","upperLimit":"3.42","value":"0.71"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"268"},{"groupId":"OG001","value":"271"}],"units":"Participants"}],"description":"Event-free survival (EFS) is the time from randomization to the earliest date of either refractory disease (or treatment failure \\[TF\\]), relapse, or death from any cause. Refractory disease is defined as complete remission never achieved during Induction (CR: \\>1000 neutrophils, \\>100,000 platelets, \\<5% blasts, and other \\[defined as absence of extramedullary disease \\[EMD\\], blasts with rods, and leukemic blasts\\]). For refractory disease, EFS event date is Day 1 (randomization). Relapse after CR is defined as ≥5% blasts, leukemic blasts, extramedullary leukemia, and presence of rods. This analysis is based on a response assessment with TF defined as not achieving response of CR, using a 42- day window from the start of the last cycle in Induction for CR evaluation.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who were randomized to receive quizartinib treatment regimen.","id":"OG000","title":"Quizartinib"},{"description":"Participants who were randomized to receive placebo treatment regimen.","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"Event-free survival was assessed in the Intent-to-Treat Analysis Set.","reportingStatus":"POSTED","timeFrame":"Date of randomization to the date of refractory disease, relapse, or death, up to approximately 3 years after enrollment","title":"Event-free Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia","type":"SECONDARY","unitOfMeasure":"months"}